NCT03662568View on ClinicalTrials.gov

A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

July 31, 2018

Study Completion Date

June 10, 2019

Conditions
Chronic Hepatitis B
Interventions
DRUG

GLS4

Administered GLS4 120 mg orally three times daily in fed state

DRUG

RTV

Administered RTV 100 mg orally three times daily in fed state

DRUG

ETV

Administered orally ETV 0.5 mg once daily in fasted state

DRUG

TDF

Administered TDF 300 mg orally once daily in fasted state

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03662568 - A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects | Biotech Hunter | Biotech Hunter